However, it is worth highlighting the results presented here are based on the ‘gold-standard’ neuropathological diagnosis of Alzheimer’s disease, which is by definition more sensitive and specific than any in vivo biomarker of amyloid-β or tau currently available. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.